AI assistant
Scilex Holding Co — Director's Dealing 2025
Oct 9, 2025
33752_dirs_2025-10-09_c755fb5f-e3fd-4f2e-96bc-a17651faf807.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Scilex Holding Co (SCLX)
CIK: 0001820190
Period of Report: 2025-10-08
Reporting Person: Ma Stephen Hoi (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-08 | Incentive Stock Option (right to buy) | $17.58 | A | 60000 | Acquired | 2035-10-08 | Common Stock (60000) | Direct |
Footnotes
F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Notwithstanding the preceding sentence, the shares of Common Stock subject to the Option will not be exercisable until such date as the Issuer's outstanding indebtedness under the Senior Secured Promissory Note issued by the Issuer to Oramed Pharmaceuticals, Inc. on September 21, 2023 and the Tranche B Senior Secured Convertible Notes issued by the Issuer to each of Oramed Pharmaceuticals, Inc., Nomis Bay Ltd., 3i LP and BPY Limited, has been repaid in full.